Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $8.6 million.

  • Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) fell 172.43% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 176.46%. This contributed to the annual value of $35.5 million for FY2024, which is 3667.23% up from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) stood at $8.6 million, which was down 172.43% from $8.6 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Depreciation & Amortization (CF) high stood at $9.1 million for Q4 2024, and its period low was $3.1 million during Q2 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $5.4 million (2023), whereas its average is $6.3 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) skyrocketed by 6892.67% in 2024 and then crashed by 274.2% in 2025.
  • Ultragenyx Pharmaceutical's Depreciation & Amortization (CF) (Quarter) stood at $3.5 million in 2021, then soared by 40.27% to $5.0 million in 2022, then skyrocketed by 65.79% to $8.2 million in 2023, then increased by 10.48% to $9.1 million in 2024, then fell by 5.21% to $8.6 million in 2025.
  • Its Depreciation & Amortization (CF) was $8.6 million in Q3 2025, compared to $8.6 million in Q2 2025 and $9.0 million in Q1 2025.